Launch Of Vyvgart Exceeds Argenx’s Expectations
‘Pipeline in A Product’ Off To Strong Start In US
Tim Van Hauwermeiren, CEO of Argenx, has been on the road with the firm's field force for the US launch of Vyvgart for generalized myasthenia gravis and has been enthused by the positive response from physicians.
You may also be interested in...
With positive Phase III data for the injectable version of its myasthenia gravis therapy, the company expects most patients to use it over intravenous Vyvgart, opening more avenues for reimbursement.
Successful Phase III data for UCB’s C5 inhibitor zilucoplan adds to a similarly positive Phase III readout for its rozanolixizumab in December, but details are lacking. UCB is the only company with two mechanisms for MG.
Two European companies - the Belgian-Dutch biotech Argenx and Calliditas of Sweden - are going it alone to commercialize their just-approved rare disease therapies in the US.